Collegium Files Pro Forma Financials for AZSTARYS Acquisition
COLL sits 24% above its 52-week low of $29.19.
Summary
Collegium Pharmaceutical filed an amendment to its May 12, 2026 8-K, providing detailed historical and pro forma financial statements related to the completed $650 million AZSTARYS acquisition.
Key Events · M&A and Partnerships · COLL
-
Acquisition Financial Details
Provides historical financial statements for Corium Therapeutics Holdings, LLC and unaudited pro forma financial information for Collegium, reflecting the AZSTARYS acquisition.
-
Completed AZSTARYS Acquisition
Follows the May 12, 2026 announcement of the completion of the $650 million acquisition of AZSTARYS, with potential additional milestone payments up to $135 million.
-
Funding Structure
The acquisition was funded by approximately $355.6 million of existing cash and a $300.0 million delayed draw term loan.
Analysis · COLL · Life Sciences
This 8-K/A provides the required historical financial statements of Corium Therapeutics Holdings, LLC (the acquired entity) and pro forma financial information for Collegium Pharmaceutical, Inc. following the completion of the $650 million AZSTARYS acquisition on May 12, 2026. These detailed financials are crucial for investors to understand the full financial impact and future outlook of the combined entity.
At the time of this filing, COLL was trading at $36.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $29.19 to $50.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.